Get the Stockscreener App
3.84
3.52%
-0.14
After Hours:
3.82
-0.02
-0.52%
Femasys Inc stock is traded at $3.84, with a volume of 53,509.
It is down -3.52% in the last 24 hours and down -46.16% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$3.98
Open:
$4.01
24h Volume:
53,509
Relative Volume:
1.05
Market Cap:
$11.60M
Revenue:
$2.38M
Net Income/Loss:
$-12.40M
P/E Ratio:
-0.5942
EPS:
-6.4626
Net Cash Flow:
$-18.68M
1W Performance:
-26.86%
1M Performance:
-46.16%
6M Performance:
-77.51%
1Y Performance:
-78.90%
1-Day Range:
$3.77
$4.15
1-Week Range:
$3.77
$5.285
52-Week Range:
$3.77
$22.20
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
3.84 | 12.02M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
FEMY Stock Price, Quote & Chart - ChartMill
FEMY Q1 2026 Earnings: EPS Surprises to the Upside as Narrower Loss Drives Stock HigherBalance Sheet Strength - newsline.com
Femasys Inc. (FEMY) Edges Higher as Stock Tests Key Resistance LevelsWMA Signal - newsline.com
Femasys, Inc. Hits New 52-Week Low at $5.08 Amid Market Challenges - MarketsMojo
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Surprises to the Upside Despite Stock DeclineEstimate Dispersion - newsline.com
Femasys Inc. (FEMY) Shares Decline 14% as Price Tests Support Near $0.29Dark Pool Prints - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Implementation - TipRanks
Femasys (NASDAQ: FEMY) implements 1-for-20 reverse stock split - Stock Titan
Femasys (FEMY) Slides 2.96% as Shares Test Key Support LevelVolume Spike Alerts - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Initiative - TipRanks
Femasys to implement 1-for-20 reverse stock split; trading symbol FEMY unchanged - TradingView
Reverse split will consolidate Femasys (NASDAQ: FEMY) common shares 20-to-1 - Stock Titan
Femasys, Inc. Financial Disclosures & SEC Filings - TradingView
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Revenue UncertaintyRevenue Growth Report - newsline.com
FEMY Technical Analysis & Stock Price Forecast - Intellectia AI
Femasys Inc. (FEMY) Edges Higher as Key Support Holds at $0.37Technical Analysis Picks - The Legal Advocate
Femasys Inc. (FEMY) Edges Higher: Navigating Key Support and Resistance LevelsCumulative Volume - newsline.com
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Beat Drives 29.85% Stock SurgeMid-Term Outlook - newsline.com
Femasys Analyst Ratings and Price Targets | NASDAQ:FEMY - Benzinga
Femasys Jumps Almost 30% as Nasdaq Deadline Remains - TechStock²
FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - Sahm
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA) - The Globe and Mail
Femasys receives CE Mark approval for FemHSG fertility catheter - Investing.com UK
Femasys updates corporate presentation on women’s health portfolio - TipRanks
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Femasys posts updated corporate presentation detailing fertility and FemBloc commercialization plans - TradingView
Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategy - Stock Titan
Femasys receives CE Mark approval for FemHSG fertility catheter By Investing.com - Investing.com South Africa
Lake Street Remains a Buy on Femasys (FEMY) - The Globe and Mail
Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter - TradingView
TradingKey - TradingKey
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns - The Globe and Mail
Femasys Inc. Announces Financial Results for Quarter Ending March 31, 2026 - geneonline.com
Femasys Inc. Q1 2026 Financials: Revenue Growth, Forward-Looking Statements, and Market Strategy - Minichart
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
FEMASYS INC 1Q 2026: Revenue $424.9K, Net income $328.6K, EPS $0— 10-Q Summary - TradingView
Non-cash gains lift Femasys (NASDAQ: FEMY) to Q1 profit amid cash strain - Stock Titan
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - The Manila Times
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMY | Femasys Inc. Common Stock Insider Trading - Quiver Quantitative
How Femasys (FEMY) maintains its asset base | Q4 2025: Better Than ExpectedWeak Earnings Momentum - newsline.com
Why Femasys (FEMY) valuation makes sense when you dig deeper (Steady Decline) 2026-05-07Earnings Beat Stocks - The Legal Advocate
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Femasys Enables OB/GYNs to Deliver First-Line Fertility - GlobeNewswire
MSN Money - MSN
The inflation impact visible in Femasys (FEMY) results | Q4 2025: EPS Tops ViewsEPS Guidance Update - newsline.com
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.68%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):